Brian Englund, PA Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 9094 E Mineral Cir, Suite 100, Centennial, CO 80112 Phone: 303-694-3200 Fax: 303-694-2680 |
Mrs. Erin Colleen Jacob, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 5555 E Arapahoe Rd, Centennial, CO 80122 Phone: 303-338-4545 |
Mrs. Heather Marie Murray, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 7336 S Yosemite St Ste 100, Centennial, CO 80112 Phone: 303-791-0410 |
Tracey Renee Connell, PA Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 5555 E Arapahoe Rd, Centennial, CO 80122 Phone: 303-338-4545 |
Taylor Lynn Sweigart, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 5657 S Himalaya St, Centennial, CO 80015 Phone: 303-699-6200 |
News Archive
Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre.
An increase in prescription drug fraud has caused doctors and hospital administrators to call for legislation to provide stronger safeguards. They say that such measures are especially important to protect government programs such as Medicaid and that heath reform proposals should increase coverage for drug treatment and rehabilitation. They note that prescription drug abuse and Medicaid fraud are especially sensitive issues in rural areas that struggle to attract providers.
Fructose, the sugar widely used as high-fructose corn syrup in soft drinks and processed foods, often gets some of the blame for the widespread rise in obesity. Now a laboratory study has found that when fructose is present as children's fat cells mature, it makes more of these cells mature into fat cells in belly fat and less able to respond to insulin in both belly fat and fat located below the skin.
Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.
› Verified 9 days ago